BR0003875A - Proceso para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico - Google Patents

Proceso para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico

Info

Publication number
BR0003875A
BR0003875A BR0003875-0A BR0003875A BR0003875A BR 0003875 A BR0003875 A BR 0003875A BR 0003875 A BR0003875 A BR 0003875A BR 0003875 A BR0003875 A BR 0003875A
Authority
BR
Brazil
Prior art keywords
formula
manufacture
naoh
lipoxygenase inhibitors
strong base
Prior art date
Application number
BR0003875-0A
Other languages
English (en)
Inventor
Timothy Norris
Megan E Hnatow
John Francis Lambert
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0003875A publication Critical patent/BR0003875A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Patente de Invenção: "PROCESSO PARA A FABRICAçãO DEINIBIDORES DE 5-LIPOXIGENASE TENDO VARIADOSSISTEMAS EM ANEL HETEROCìCLICO". é descrito um processopara a preparação de um composto de Fórmula (1.3.0):compreendendo: a formação de uma mistura reacional constituídapor num solvente aprótico; na presença de uma base forte emforma sólida selecionada do grupo constituído por hidróxido desódio, NaOH, e hidróxido de potássio, KOH; e, facultativamente,na presença de uma quantidade catalítica de carbonato de césio,Cs~ 2~CO~ 3~, ou de um catalisador de transferência de fase,especialmente um sal de amónio quaternário ou um sal de fosfónioseguido por - aquecimento da referida mistura reacional sob umaatmosfera de nitrogênio; por meio do que é produzido um compostode Fórmula (1.3.0); e numa modalidade preferida o solventeaprótico é DMSO, a base forte em forma sólida é NAOH em formade pó ou péletes, e o catalisador de transferência de fase é cloretode tetra-n-butilamónio (TBAC), a qual é usada para preparar umcomposto preferido, útil como inibidor de 5-lipoxigenase, da fórmulaespecialmente o seu sal metanossulfonato substancialmente puro.
BR0003875-0A 1999-08-31 2000-08-30 Proceso para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico BR0003875A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161199P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
BR0003875A true BR0003875A (pt) 2001-12-11

Family

ID=22539515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0003875-0A BR0003875A (pt) 1999-08-31 2000-08-30 Proceso para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico

Country Status (19)

Country Link
US (1) US6344563B1 (pt)
EP (1) EP1081146A1 (pt)
JP (1) JP2001106687A (pt)
KR (1) KR20010050224A (pt)
CN (1) CN1291609A (pt)
AR (1) AR022649A1 (pt)
AU (1) AU5360700A (pt)
BR (1) BR0003875A (pt)
CA (1) CA2317001A1 (pt)
CZ (1) CZ20003160A3 (pt)
HU (1) HUP0003438A3 (pt)
ID (1) ID29315A (pt)
IL (1) IL138088A0 (pt)
MX (1) MXPA00008505A (pt)
PL (1) PL342284A1 (pt)
RU (1) RU2177005C1 (pt)
TR (1) TR200002523A2 (pt)
YU (1) YU52800A (pt)
ZA (1) ZA200004436B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4589701A (en) 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1050840C (zh) * 1993-06-14 2000-03-29 美国辉瑞有限公司 咪唑脂氧合酶抑制剂
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
WO1997011079A1 (en) * 1995-09-18 1997-03-27 Pfizer Pharmaceuticals Inc. Novel imidazole lipoxygenase inhibitors

Also Published As

Publication number Publication date
JP2001106687A (ja) 2001-04-17
RU2177005C1 (ru) 2001-12-20
HUP0003438A3 (en) 2002-08-28
CN1291609A (zh) 2001-04-18
ID29315A (id) 2001-08-16
HU0003438D0 (en) 2000-08-30
KR20010050224A (ko) 2001-06-15
EP1081146A1 (en) 2001-03-07
CA2317001A1 (en) 2001-02-28
TR200002523A2 (tr) 2001-04-20
AR022649A1 (es) 2002-09-04
ZA200004436B (en) 2002-02-28
MXPA00008505A (es) 2005-07-25
CZ20003160A3 (cs) 2001-10-17
YU52800A (sh) 2003-08-29
AU5360700A (en) 2001-03-08
US6344563B1 (en) 2002-02-05
PL342284A1 (en) 2001-03-12
IL138088A0 (en) 2001-10-31
HUP0003438A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
Lebleu et al. Selective monomethylation of primary amines with simple electrophiles
BR0005488A (pt) Processo para a preparação de carbonato de vinileno, e o uso do mesmo
BR0310005A (pt) Método para a produção de ácido orgânico
CO5720995A2 (es) Compuesto novedoso
AR011626A1 (es) Un procedimiento para la elaboracion de compuestos epoxidos, resinas epoxidas obtenidas mediante dicho procedimiento y un procedimiento para laelaboracion de compuestos intermedios para la elaboracion de compuestos epoxidos
EP2581342A3 (en) Method for the production of fertilizer and CO2
BR0003875A (pt) Proceso para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico
Yang et al. Clean and economic synthesis of alkanesulfonyl chlorides from S-alkyl isothiourea salts via bleach oxidative chlorosulfonation
ES2189499T3 (es) Composicion y proceso para eliminacion de gases acidos.
KR927003523A (ko) 알킬 폴리에톡시에테르 설페이트의 제조방법
Li et al. A robust and facile method for desulfonation to amines
RU2217434C1 (ru) Способ получения высокочистого цефподоксима проксетила
Kishi et al. Prins Cyclization in Ionic Liquid Hydrogen Fluoride Salts: Facile and Highly Efficient Synthesis of 4‐Fluorinated Tetrahydropyrans, Thiacyclohexanes, and Piperidines
AR029767A1 (es) Procedimiento para la preparacion de compuestos de pirazolo (4, 3-d) pirimidin-7-onas-3-piridilsulfonilo y compuestos intermediarios utiles en dicho procedimiento.
AR021268A1 (es) Proceso para preparar compuestos acilaromaticos
BR0114753A (pt) Processo para a preparação de compostos de bis-benzazolila
ES414365A1 (es) Procedimiento para la preparacion de nuevos derivados del acido p-dihidroxibencenodisulfonico.
AR015571A1 (es) Procedimiento para la elaboracion de compuestos derivados de alfa-bromo-lactama y el uso de dichos compuestos para la preparacion de cefalosporinas
BR0003569A (pt) Resóis, processo para a sua preparação e aplicação
BR0315671A (pt) Processo para a preparação de um composto
BR0003888A (pt) Processo para a fabricação de inibidores de5-lipoxigenase tendo variados sistemas em anelheterocìclico
JPS55139350A (en) Amino compound
JPS52116438A (en) Preparation of styrene sulfonic acid salts
BR0003301A (pt) Processo para a preparação de arilaminohidroxiantraquinonas
PA8499701A1 (es) Procedimiento para preparar inhibidores de 5-lipoxigenasa que tienen sistemas variados de anillos heterocíclicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A, 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.